PolyNovo releases FY26 Annual Report
Released on September 14, 2026, the document includes the annual report and corporate governance statement.
See the latest news and media coverage for PolyNovo. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of synthetic skin substitutes
polynovo.comLast updated
In short: PolyNovo posted record $150M FY26 revenue but underwent leadership upheaval with its CEO ousted and chair resignation.
Released on September 14, 2026, the document includes the annual report and corporate governance statement.
The organization expands its NovoSorb platform to over fifty countries while leveraging a robust evidence base of five hundred thirty clinical publications.
Commercial sales rose 16.7% to $138.4m with manufacturing output increasing significantly as new facility construction completed.
The announcement includes financial performance data and Appendix 4E documents released on August 26, 2026.
PolyNovo Limited (ASX:PNV) disclosed FY26 revenue of $150 million, up 16% on FY25, and underlying EBITDA of $13.4 million, representing a 50.4% year-on-year increase, as...
Polynovo ( ($AU:PNV) ) has issued an announcement. In FY26 PolyNovo recorded revenue of $150 million, up 16% on the prior year and roughly 39...
PolyNovo’s latest half-year filing on 25 August 2026 told a mixed story. Revenue reached A$79.522 million, while net income ...
PolyNovo chief financial officer Jan Gielen will step down to join Vitrafy Life Sciences after eight years with the company.
Track PolyNovo and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to PolyNovo and other trending companies.